Hot news
- Leadman | The first team develo
- 2016 | The First Staff Birthday
- Leadman Self-directed Spring Ae
- 2016| International Women's day
- 2016 Leadman Annual Meeting
- 25/12/2015 | Merry Christmas +
- Creativity、 Modern and Effici
- State Food and Drug Administrat
- Thanksgiving | Leadman special
- The Week of Sincerity Construct
- Leadman Participated The 74th C
- Leadman Was one of The GEM List
- HAPPY LEADMAN| Enterprise Image
- Shen Guangqian---Leadman’s CH
- Leadman Marketing Team Particip
- Leadman Hold The First session
- 2015＂ Leadman first session o
- Runing, Bloomimg Leadman—2015
- The reserved restricted shares
- Resolution of the 25th Conferen
- Resolution of the 24th Conferen
- 2014 Annual Earnings Preannounc
- The legal opinion about adjusti
- Leadman Christmas Gourmet Festi
- Leadman Signs Significant Daily
- Leadman was cited for its excel
- Leadman was awarded the most be
- Resolution of the Fourth Extrao
- Additional legal opinions about
- Leadman’s Major Shareholder’
- 2014 Annual and 2015 Annual Mer
- Resolution of the 22nd Conferen
- Resolution of the 23rd Conferen
- The Independent Financial Consu
- The Management System of the Ra
- The General Risk Warning Notice
- The Financial Report and Audit
- The Notice of Fourth Extraordin
- The Independent Directors’ Op
- Leadman Held Investor Meeting
- Leadman attends the 72th CMEF-
- “Leadman” and“Enigma”es
- Leadman invites you to the 72th
- Leadman join hands with global
- Leadman’s new official websit
- Leadman with IDS team visiting
- Leadman awarded GEM Top 50 ente
- Leadman’s new product CI1000
- Medical Equipment Quality Journ
- Leadman holds 2014 Debate Conte
Sanofi-Aventis invests $2.1m in Hadasit Bio portfolio co Kahr
作者：Leadman日期：2011-04-18
Hadasit Bio is also investing $1 million in the company, which is developing protein-based drugs for autoimmune diseases and cancer.
Gali Weinreb Published by Globes [online], Israel business news - www.globes-online.com
Sanofi-Aventis SA (NYSE; Euronext: SNY) is investing $2.1 million in Hadasit Bio Holdings Ltd. (TASE:HDST) portfolio company KAHR Medical Ltd. at a company value of $5.5 million, before money. Hadasit Bio is also investing $1 million in the company and will convert a $2.1 million owner's loan into shares at a 20-30% discount on the price in the original investment agreement.
When the deal is closed, Hadasit Bio will own 65% of Kahr and Sanofi-Aventis will own 18%, and will have first rights to negotiate to buy Kahr's leading product. Kahr is developing protein-based drugs for autoimmune diseases and cancer.
Hadasit Bio CEO Ophir Shahaf told "Globes" that other portfolio company, Enlivex Therapeutics Ltd., is also in talks with a strategic investor. Enlivex is cell therapies for the induction of immune tolerance in autoimmune and inflammatory conditions such as graft versus host disease, solid organ transplant rejection, and Crohn’s disease.
Shahaf said that a third company, BioMarCare Technologies Ltd., is in talks with a financial investor. BioMarCare is developing next-generation molecular and serum-based diagnostic biomarkers for breast and colon cancers.
Shahaf added that Hadasit Bio was seeking new activities, and that it was in talks with two companies whose intellectual property rights were not from Hadassah Medical Organization.
"We're developing a new model, under which we'll carry out a test for our own due diligence.We're prepared to finance such a test in exchange for options, in order to improve our assurance about the product that we're buying and investing in."
